Expanded indiction allows earlier radioligand therapy in PSMA-positive metastatic hormane-sensitive prostate cancer based on phase 3 PSMAddition trial data.

Nearly 1 in 6 parents say their 18- to 25-year-old does not handle any basic health care responsibilities on their own ...

Significant improvement seen in clinical efficacy with press-needle therapy; therapy plus medication superior to medication alone ...

The FTC alleges most consumers never get a consultation, instead, they are billed and enrolled in recurring subscription plans shortly after submitting the form.

Midazolam HCl 1mg/mL or 5mg/mL; soln for IV or IM inj; contains benzyl alcohol. Individualize, titrate slowly, see literature. Sedation/anxiolysis/amnesia (IM): 0.1–0.15mg/kg; more anxious may use up ...

Shionogi’s oral main protease inhibitor Xocova (ensitrelvir) is now available in the US to reduce the risk of symptomatic ...

Cancer progression within 36 months of combination therapy identified patients with overall survival of less than 2 years.

Despite noting the high unmet need in Duchenne muscular dystrophy, the FDA panel concluded that trial data lacked substantial evidence of the therapy's effectiveness.

Ziltivekimab failed to reduce the risk of 3-point MACE (HR, 0.99) vs placebo in adults with ASCVD, CKD, and CV inflammation. Topline data were announced from a phase 3 trial evaluating ziltivekimab in ...

As number of risk factors increased, increase was seen in number of plaques and plaques with vulnerable phenotype.

The sBLA is supported by phase 1b/2 OrigAMI-4 trial data demonstrating a 42% confirmed overall response rate in pretreated ...

Gywn Lo demonstrated high contraceptive efficacy (Pearl Index 4.14), progressive cycle control, and excellent patch adhesion across diverse real-world conditions. The Food and Drug Administration (FDA ...